SCHEMBL2927320

SCHEMBL2927320

Cc1cc(-c2cnc(N)c(-c3ccc(O)cc3)n2)ccc1S(=O)(=O)N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 2/20 0.48
CCNE1 P24864 2/20 0.48
CDK2 P24941 2/20 0.48
GSK3B P49841 2/20 0.48
ALDH1A1 P00352 2/20 0.45
CNR1 P21554 6/20 0.44
CNR2 P34972 6/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 2/20 0.44
KMT2A Q03164 1/20 0.44
ALOX5AP P20292 4/20 0.43
FEN1 P39748 4/20 0.43
PIK3CA P42336 1/20 0.42
LMNA P02545 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
KCNH2 Q12809 1/20 0.41
CHEK1 O14757 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2936491 0.89 ALOX5AP (0.50) CCNE2CCNE1CDK2GSK3BALOX5AP
SCHEMBL2927141 0.89 GSK3B (0.59) CCNE2CCNE1CDK2GSK3BMAPT
SCHEMBL2935457 0.84 ALDH1A1 (0.50) ALDH1A1CNR1CNR2MAPTTP53
SCHEMBL2933507 0.84 CCNE2 (0.56) CCNE2CCNE1CDK2GSK3BALDH1A1
SCHEMBL2925588 0.80 LRRK2 (0.56) ALOX5APFEN1PIK3CAKCNH2CHEK1
SCHEMBL2927137 0.80 GSK3B (0.61) CCNE2CCNE1CDK2GSK3BALOX5AP
SCHEMBL2931745 0.75 SLC2A1 (0.46) CCNE2CCNE1CDK2GSK3BABL1
SCHEMBL2932840 0.74 LRRK2 (0.55) CCNE1CDK2MAPTALOX5APFEN1
SCHEMBL2927198 0.74 ALOX5AP (0.46) CCNE2CCNE1CDK2GSK3BALDH1A1
SCHEMBL2934913 0.73 ATR (0.67) KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 CCNE2 806/4885CCNE1 527/4885CDK2 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.